S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

JNJ Johnson and Johnson

157.47

3.56 (2.31%)

Apr 17 2025 - Closed

Delayed by 15 minutes

Form 5 - Annual statement of changes in beneficial ownership of securities

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2025 to Apr 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2024 to Apr 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson News

Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
Wednesday 16 April 2025 (3 days ago) • Business Wire

NYSE Content Advisory: Pre-Market update + Bank of America beats earnings estimates
Tuesday 15 April 2025 (4 days ago) • PR Newswire (US)

Form 8-K - Current report
Tuesday 15 April 2025 (4 days ago) • Edgar (US Regulatory)

Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%
Tuesday 15 April 2025 (5 days ago) • Business Wire

Johnson & Johnson Reports Q1 2025 Results
Tuesday 15 April 2025 (5 days ago) • Business Wire

Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
Thursday 10 April 2025 (1 week ago) • PR Newswire (US)

Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)
Tuesday 8 April 2025 (2 weeks ago) • PR Newswire (US)

Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
Monday 7 April 2025 (2 weeks ago) • Business Wire

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
Friday 4 April 2025 (2 weeks ago) • PR Newswire (US)

Form 8-K - Current report
Thursday 3 April 2025 (2 weeks ago) • Edgar (US Regulatory)

Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
Wednesday 2 April 2025 (2 weeks ago) • Business Wire

Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition
Tuesday 1 April 2025 (3 weeks ago) • Business Wire

More Johnson and Johnson News Articles

ERHC Energy (CE)

Voip Pal Com (QB)

TheGlobe com (PK)

Anavex Life Sciences

North Bay Resources (PK)

Bioelectronics (PK)

Liquidmetal Technologies (QB)

Digital Brand Media and ... (PK)

Elite Pharmaceuticals (QB)

Asia Broadband (PK)

Northwest Biotherapeutics (QB)

Lightwave Logic

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions